Evidence map›Paper›PMID 34348721›Full record

ArticleJournal of nanobiotechnology2021

Platelet membrane-camouflaged silver metal-organic framework drug system against infections caused by methicillin-resistant Staphylococcus aureus.

Rong Huang, Guang-Qing Cai, Jian Li, Xi-Sheng Li, Hai-Ting Liu, Xue-Ling Shang, Jian-Dang Zhou, Xin-Min Nie, Rong Gui

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 97 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Homotypic Membrane Vesicle-Formulated VAN@Biomaterials research · 2025
    Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Rong HuangDepartment of Blood Transfusion, The Third Xiangya Hospital, Central South University, Hunan, Changsha, China.
Guang-Qing CaiDepartment of Orthopedics, Changsha Hospital of Traditional Chinese Medicine, Changsha Eighth Hospital, Hunan, Changsha, China.
Jian LiDepartment of Blood Transfusion, The Third Xiangya Hospital, Central South University, Hunan, Changsha, China.
Xi-Sheng LiDepartment of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Hunan, Changsha, China.
Hai-Ting LiuDepartment of Blood Transfusion, The Third Xiangya Hospital, Central South University, Hunan, Changsha, China.
Xue-Ling ShangDepartment of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Hunan, Changsha, China.
Jian-Dang ZhouDepartment of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Hunan, Changsha, China.
Xin-Min NieDepartment of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Hunan, Changsha, China. niexinmin@csu.edu.cn.ORCID http://orcid.org/0000-0003-3104-2505
Rong GuiDepartment of Blood Transfusion, The Third Xiangya Hospital, Central South University, Hunan, Changsha, China. guirong@csu.edu.cn.
Central South University · CNThe Eighth Hospital of Xi'an · CN

Funding

National Natural Science Foundation of China 81602801National Natural Science Foundation of China 81971748Natural Science Foundation of Hunan Province 2019JJ40464
6 · The paper itself

Abstract

backgroundDue to the intelligent survival strategy and self-preservation of methicillin-resistant Staphylococcus aureus (MRSA), many antibiotics are ineffective in treating MRSA infections. Nano-drug delivery systems have emerged as a new method to overcome this barrier. The aim of this study was to construct a novel nano-drug delivery system for the treatment of MRSA infection, and to evaluate the therapeutic effect and biotoxicity of this system. We prepared a nano silver metal-organic framework using 2-methylimidazole as ligand and silver nitrate as ion provider. Vancomycin (Vanc) was loaded with Ag-MOF, and nano-sized platelet vesicles were prepared to encapsulate Ag-MOF-Vanc, thus forming the novel platelet membrane-camouflaged nanoparticles PLT@Ag-MOF-Vanc.

resultsThe synthesized Ag-MOF particles had uniform size and shape of radiating corona. The mean nanoparticle size and zeta potential of PLT@Ag-MOF-Vanc were 148 nm and - 25.6 mV, respectively. The encapsulation efficiency (EE) and loading efficiency (LE) of vancomycin were 81.0 and 64.7 %, respectively. PLT@Ag-MOF-Vanc was shown to be a pH-responsive nano-drug delivery system with good biocompatibility. Ag-MOF had a good inhibitory effect on the growth of three common clinical strains (Escherichia coli, Pseudomonas aeruginosa, and S. aureus). PLT@Ag-MOF-Vanc showed better antibacterial activity against common clinical strains in vitro than free vancomycin. PLT@Ag-MOF-Vanc killed MRSA through multiple approaches, including interfering with the metabolism of bacteria, catalyzing reactive oxygen species production, destroying the integrity of cell membrane, and inhibiting biofilm formation. Due to the encapsulation of the platelet membrane, PLT@Ag-MOF-Vanc can bind to the surface of the MRSA bacteria and the sites of MRSA infection. PLT@Ag-MOF-Vanc had a good anti-infective effect in mouse MRSA pneumonia model, which was significantly superior to free vancomycin, and has no obvious toxicity.

conclusionsPLT@Ag-MOF-Vanc is a novel effective targeted drug delivery system, which is expected to be used safely in anti-infective therapy of MRSA.

Indexed as

AnimalsAnti-Bacterial AgentsDisease Models, AnimalDrug CarriersEscherichia coliMaleMetal-Organic FrameworksMethicillin-Resistant Staphylococcus aureusMiceMicrobial Sensitivity TestsNanoparticle Drug Delivery SystemNanoparticlesPseudomonas aeruginosaRAW 264.7 CellsStaphylococcus aureusVancomycinAnti-Bacterial AgentsDrug CarriersMetal-Organic FrameworksNanoparticle Drug Delivery SystemVancomycinMetal-organic frameworkMethicillin-resistantPlateletStaphylococcus aureusVancomycin

Identifiers

PMID34348721
PMCPMC8336064
OpenAlexW3162463107

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.